# 16S ribosomal ribonucleic acid sequencing reveals bile microbiome features in gallstone disease and their links to blood lipid subtypes

**Authors:** Shijie Wang, Yongxing Ding, Cheng Cai, Mingrui Ou, Chunshen Niu

PMC · DOI: 10.3389/fmicb.2026.1741489 · Frontiers in Microbiology · 2026-02-16

## TL;DR

This study shows that the bile microbiome in gallstone disease differs between patients with high triglycerides and others, suggesting a link to blood lipid levels and possible metabolic pathways.

## Contribution

The study identifies specific bile microbiome features associated with distinct lipid subtypes in gallstone disease patients.

## Key findings

- Bile microbiome composition differed between hypertriglyceridaemia and non-HTG groups, with Proteobacteria and Firmicutes showing group-specific trends.
- Microbial diversity was reduced in the HTG group, and random forest classification achieved moderate accuracy in predicting lipid subtypes.
- Potential mechanistic links were suggested through bile acid metabolism and farnesoid X receptor–fibroblast growth factor 19 signaling pathways.

## Abstract

Gallstone disease (GSD) represents a major global health burden with complex pathophysiology involving bile microbiome dysbiosis and metabolic dysfunction. Although previous studies have examined bile microbial communities, the relationship between bile microbiome composition and specific lipid phenotypes remains incompletely understood.

We conducted a cross-sectional study of 28 adults undergoing cholecystectomy for radiologically and pathologically confirmed gallstones. Bile samples were collected intraoperatively and subjected to 16S ribosomal ribonucleic acid V3–V4 region sequencing. Patients were stratified by lipid subtypes based on contemporary dyslipidaemia guidelines. Microbial diversity, community structure and differential abundance analyses were performed alongside machine learning classification.

The bile microbiome exhibited distinct compositional patterns between the hypertriglyceridaemia (HTG) and non-HTG (NTG) groups, with key phyla (Proteobacteria, Firmicutes) showing group-specific abundance trends and alpha diversity indices reflecting reduced evenness in HTG. Beta diversity analyses demonstrated mild-to-moderate separation between groups, and the linear discriminant analysis effect size technique identified discriminatory taxa with potential functional relevance. Random forest classification achieved moderate accuracy in predicting lipid subtypes based on microbial features.

This study revealed associations between bile microbiome composition and systemic lipid metabolism in GSD, suggesting potential mechanistic links through bile acid metabolism and farnesoid X receptor–fibroblast growth factor 19 signaling pathways.

## Full-text entities

- **Genes:** GGT1 (gamma-glutamyltransferase 1) [NCBI Gene 2678] {aka CD224, D22S672, D22S732, GGT, GGT 1, GGTD}, LYZ (lysozyme) [NCBI Gene 4069] {aka AMYLD5, LYZF1, LZM}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, GGTLC4P (gamma-glutamyltransferase light chain 4 pseudogene) [NCBI Gene 729838] {aka GGT}, FGF19 (fibroblast growth factor 19) [NCBI Gene 9965], GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}, CYP7A1 (cytochrome P450 family 7 subfamily A member 1) [NCBI Gene 1581] {aka CP7A, CYP7, CYPVII}
- **Diseases:** GSD (MESH:D002769), lipid disturbances (MESH:D011017), disorder of cholesterol metabolism (MESH:C535937), inflammatory bowel disease (MESH:D015212), stone (MESH:D007669), digestive disorders (MESH:D004066), gastrointestinal disorders (MESH:D005767), stone formation (MESH:D058426), bile (MESH:D001649), NTG (MESH:C580335), cholangitis (MESH:D002761), metabolic disorders (MESH:D008659), acute cholangitis (MESH:D000208), cholecystitis (MESH:D002764), overweight (MESH:D050177), fatty liver (MESH:D005234), obese (MESH:D009765), malignancy (MESH:D009369), gallstone (MESH:D042882), dysbiosis (MESH:D064806), Chronic inflammation (MESH:D007249), Metabolic syndrome (MESH:D024821), gallbladder stones (MESH:D005705)
- **Chemicals:** glucose (MESH:D005947), nivolumab (MESH:D000077594), lipid (MESH:D008055), zirconia (MESH:C028541), pembrolizumab (MESH:C582435), silica (MESH:D012822), olanzapine (MESH:D000077152), NTG (-), bile acid (MESH:D001647), cholesterol (MESH:D002784), TG (MESH:D014280), bilirubin (MESH:D001663)
- **Species:** Limosilactobacillus reuteri (species) [taxon 1598], gut metagenome (species) [taxon 749906], Wolbachia (genus) [taxon 953], Lactiplantibacillus plantarum (species) [taxon 1590], Bacillota (clostridial firmicutes, phylum) [taxon 1239], Neorhizobium (genus) [taxon 1525371], Homo sapiens (human, species) [taxon 9606], Burkholderia (genus) [taxon 32008], Maribacter (genus) [taxon 252356], Pseudoalteromonas (genus) [taxon 53246], Rhizobium (genus) [taxon 379], Sphingobacterium (genus) [taxon 28453], Brevundimonas (genus) [taxon 41275], Streptococcus (genus) [taxon 1301], Pseudomonadota (proteobacteria, phylum) [taxon 1224], Caballeronia (genus) [taxon 1827195], Vibrio (genus) [taxon 662]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12951477/full.md

## Figures

12 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12951477/full.md

## References

33 references — full list in the complete paper: https://tomesphere.com/paper/PMC12951477/full.md

---
Source: https://tomesphere.com/paper/PMC12951477